Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesGastroenterologyUnivera Healthcare IBD Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentUnivera HealthcarePolicy 2.02.19

    Serum Antibodies for the Diagnosis of Inflammatory Bowel Disease

    Customize your policy alerts

    Sign up for univerahealthcare Policy 2.02.19 alerts

    Get alerted when Policy 2.02.19 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of serologic biomarker testing used to evaluate inflammatory bowel disease, including testing intended to diagnose or monitor IBD or distinguish ulcerative colitis from Crohn's disease. The policy applies to providers requesting these laboratory services for members.

    Policy Summary
    PayerUnivera Healthcare
    PolicySerum Antibodies for the Diagnosis of Inflammatory Bowel Disease
    Policy CodePolicy 2.02.19
    Change TypeAnnual reviewno material change
    Effective DateNovember 19, 2026
    Last ReviewNov 19, 2026
    Next Review DateNovember 1, 2027
    Key ActionDo not request serologic IBD biomarker testing, including Prometheus IBD sgi Diagnostic testing, because it is considered not medically necessary.
    SourceLink
    POLICY UPDATE CHANGES

    The policy underwent an annual review on November 19, 2026, with policy intent unchanged.

    Not medically necessaryCoverage stance for serologic biomarker testing
    10–15%IBD patients with indeterminate classification
    67% / 76%IBD7 panel sensitivity / specificity
    94%Specificity of three abnormal routine laboratory results
    NoneSpecific CPT code

    Coverage Criteria

    Serum antibody testing for IBD

    Serologic testing of biomarkers for inflammatory bowel disease (IBD) is considered not medically necessary for all indications, including but not limited to the following tests and uses.

    The following apply

    • Serologic biomarkers include, but are not limited to

      • Anti-neutrophil cytoplasmic antibodies (ANCA) or anti-Saccharomyces cerevisiae (ASCA).
      • Antibodies to outer membrane porin C of the bacteria Escherichia coli (anti-OmpC).
      • Pseudomonas fluorescens-associated sequence I2 (anti-I2).
      • Flagellin CBir1 (anti-CBir1).
      • Antichitobioside antibodies (ACCA IgA).
      • Antilaminaribioside antibodies (ALCA IgG).
      • Antimannobioside antibodies (AMCA IgG).
    • Testing indications include, but are not limited to

      • Diagnosing and monitoring patients with inflammatory bowel disease (IBD).
      • Distinguishing ulcerative colitis (UC) from Crohn's disease (CD).

    Serologic testing of biomarkers, including Prometheus IBD sgi Diagnostic testing, is considered not medically necessary for all indications. This determination includes testing intended to diagnose or monitor IBD or to distinguish ulcerative colitis from Crohn's disease, and is not limited to the specific biomarkers listed above.

    Coding Information

    CPT CodesCPT
    81479May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD.
    82397May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD.
    83516May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD.
    83520May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD.
    86140May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD.
    88346May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD.
    88350May be used for billing PROMETHEUS IBD sgi Diagnostic; not specific to PROMETHEUS IBD.
    HCPCS CodesHCPCS
    No codes listed
    ICD10 CodesICD-10
    K50.00-K50.919Crohn's disease [regional enteritis] (code range)
    K51.00-K51.919Ulcerative colitis (code range)

    Provider Guidance

    Denial Risk

    Serologic IBD biomarker testing is not medically necessary

    Do not request serologic IBD biomarker testing, including PROMETHEUS IBD sgi Diagnostic testing or antibody panels, because it is considered not medically necessary for all indications. This includes testing to diagnose or monitor inflammatory bowel disease or to distinguish ulcerative colitis from Crohn’s disease.

    Denial Risk

    Unsupported diagnostic or prognostic serology

    Do not use serologic antibody testing to establish or rule out ulcerative colitis, establish a diagnosis of Crohn’s disease, or determine ulcerative colitis prognosis. The American College of Gastroenterology does not support these uses.

    • Routine use of serologic markers of IBD to establish the diagnosis of Crohn’s disease is not indicated.
    • Serologic antibody testing is not recommended to establish or rule out ulcerative colitis or determine its prognosis.

    Clinical Background

    Inflammatory bowel disease (IBD) includes Crohn’s disease and ulcerative colitis. Their clinical presentations may overlap, and approximately 10–15% of patients cannot be definitively classified as having either condition and are diagnosed with indeterminate colitis. Endoscopic examination and biopsy remain important components of diagnosis.

    Definitions

    Inflammatory bowel disease (IBD)
    DefinitionA chronic disease of the gastrointestinal tract.
    Included diseasesConsists of ulcerative colitis (UC) and Crohn's disease (CD).
    Clinical contextUC and CD are distinctive forms of IBD, but their clinical presentations commonly overlap.
    Ulcerative colitis (UC)
    DefinitionA form of inflammatory bowel disease and one of its two related diseases.
    Diagnostic distinctionAlthough generally considered distinct from Crohn's disease, ulcerative colitis may be difficult to distinguish clinically because their presentations commonly overlap.
    Diagnostic contextEndoscopic examination and biopsy are currently crucial components of the diagnostic work-up.
    Crohn's disease (CD)
    DefinitionA form of inflammatory bowel disease and one of its two related diseases.
    Diagnostic distinctionAlthough generally considered distinct from ulcerative colitis, Crohn's disease may be difficult to distinguish clinically because their presentations commonly overlap.
    Diagnostic contextEndoscopic examination and biopsy are currently crucial components of the diagnostic work-up.
    Indeterminate colitis (IC)
    DefinitionA diagnosis assigned when the distinction between Crohn's disease and ulcerative colitis cannot be made with certainty.
    Patients affectedApproximately 10–15% of patients with inflammatory bowel disease cannot be definitively classified as having Crohn's disease or ulcerative colitis.
    Diagnostic contextThe distinction may remain uncertain because the clinical presentations of Crohn's disease and ulcerative colitis commonly overlap.
    PROMETHEUS IBD sgi Diagnostic
    DefinitionA proprietary test intended for patients with clinical suspicion of inflammatory bowel disease.
    Test componentsCombines serologic markers with genetic and inflammation markers.
    Intended clinical useAims to help identify inflammatory bowel disease and differentiate ulcerative colitis from Crohn's disease; it may also assess risk for more aggressive disease.
    Reported resultsThe Smart Diagnostic Algorithm produces an IBD score and reports results as consistent with IBD—including consistent with ulcerative colitis, consistent with Crohn's disease, or inconclusive for ulcerative colitis versus Crohn's disease—or not consistent with IBD.
    Policy Summary
    PayerUnivera Healthcare
    PolicySerum Antibodies for the Diagnosis of Inflammatory Bowel Disease
    Policy CodePolicy 2.02.19
    Change TypeAnnual reviewno material change
    Effective DateNovember 19, 2026
    Last ReviewNov 19, 2026
    Next Review DateNovember 1, 2027
    Key ActionDo not request serologic IBD biomarker testing, including Prometheus IBD sgi Diagnostic testing, because it is considered not medically necessary.
    SourceLink
    On This Page
    Coverage CriteriaCoding InformationProvider GuidanceClinical BackgroundDefinitions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.